Although most preclinical research on developing synthetic NFκB inhibitors for clinical applications have focused on diseases fueled by chronic inflammation [78,79], there have been efforts to both develop cancer-specific NFκB inhibitors and repurpose existing inhibitors for anti-cancer therapy due to the importance of NFκB in the regulation of apoptosis and cancer stem cell maintenance. This evidence concerns the gene NFKB1 and cancer.